Literature DB >> 8623959

The effect of dexmedetomidine on the balance of myocardial energy requirement and oxygen supply and demand.

C J Lawrence1, F W Prinzen, S de Lange.   

Abstract

The effect of the alpha(2)-adrenergic agonist dexmedetomidine on the balance between myocardial energy requirement and oxygen supply and demand was investigated in 16 open-chest dogs anesthetized with either chloralose/urethane (CU) or fentanyl/halothane (FH). Myocardial energy requirement (estimated from the pressure work index), blood flow and its transmural distribution (radioactive microspheres), as well as myocardial oxygen and lactate extraction, were measured before and after administration of dexmedetomidine in doses ranging from 0.1 to 10 micrograms/kg intravenously. Under CU anesthesia, dexmedetomidine decreased heart rate, arterial blood pressure, and cardiac output. During FH anesthesia, dexmedetomidine reduced heart rate and cardiac output whereas arterial blood pressure increased. Dexmedetomidine decreased myocardial energy requirement only during CU anesthesia; myocardial oxygen supply and demand decreased in parallel. At the (large) dose of 10 micrograms/kg, myocardial oxygen extraction increased during both types of anesthesia. Dexmedetomidine >/= 1 microgram/kg increased endocardial/epicardial blood flow ratio during FH anesthesia. These data indicate that dexmedetomidine >/= 1 microgram/kg reduces myocardial energy requirements, especially when baseline heart rate and blood pressure are increased. Dexmedetomidine preserves endocardial perfusion and reduces oxygen demand in parallel with oxygen supply and energy requirements.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8623959     DOI: 10.1097/00000539-199603000-00021

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  9 in total

1.  Dexmedetomidine.

Authors:  N Bhana; K L Goa; K J McClellan
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

2.  Use of dexmedetomidine in a pediatric heart transplant patient.

Authors:  C Chrysostomou; T Zeballos
Journal:  Pediatr Cardiol       Date:  2005 Sep-Oct       Impact factor: 1.655

3.  Dexmedetomidine infusion for analgesia up to 48 hours after lung surgery performed by lateral thoracotomy.

Authors:  Michael A E Ramsay; Kate B Newman; Barbara Leeper; Baron L Hamman; Robert F Hebeler; A Carl Henry; Harry Kourlis; Richard E Wood; Jack A Stecher; H A Tillmann Hein
Journal:  Proc (Bayl Univ Med Cent)       Date:  2014-01

4.  The Impact of Dexmedetomidine Initiation on Cardiovascular Status and Oxygenation in Critically ill Neonates.

Authors:  Christopher McPherson; Caren J Liviskie; Brandy Zeller; Zachary A Vesoulis
Journal:  Pediatr Cardiol       Date:  2022-02-25       Impact factor: 1.838

5.  The use of dexmedetomidine continuous rate infusion for horses undergoing transvenous electrical cardioversion--A case series.

Authors:  Charlotte Marly-Voquer; Colin C Schwarzwald; Regula Bettschart-Wolfensberger
Journal:  Can Vet J       Date:  2016-01       Impact factor: 1.008

6.  Perioperative dexmedetomidine improves mortality in patients undergoing coronary artery bypass surgery.

Authors:  Fuhai Ji; Zhongmin Li; Nilas Young; Peter Moore; Hong Liu
Journal:  J Cardiothorac Vasc Anesth       Date:  2013-10-29       Impact factor: 2.628

7.  The myocardial protective effect of dexmedetomidine in high-risk patients undergoing aortic vascular surgery.

Authors:  Rabie Soliman; Gomaa Zohry
Journal:  Ann Card Anaesth       Date:  2016 Oct-Dec

8.  Dexmedetomidine intravenous sedation using a patient-controlled sedation infusion pump: a case report.

Authors:  Seong In Chi; Hyun Jeong Kim; Kwang-Suk Seo
Journal:  J Dent Anesth Pain Med       Date:  2016-03-31

9.  Dexmedetomidine versus ketofol sedation for outpatient diagnostic transesophageal echocardiography: A randomized controlled study.

Authors:  S Sruthi; Banashree Mandal; Manoj K Rohit; Goverdhan Datt Puri
Journal:  Ann Card Anaesth       Date:  2018 Apr-Jun
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.